Last reviewed · How we verify
Acide Tranexamique
Acide Tranexamique is a Small molecule drug developed by Centre Hospitalier de Montauban. It is currently FDA-approved. Also known as: Exacyl.
Acide Tranexamique, marketed by Centre Hospitalier de Montauban, is an established drug with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging its well-established mechanism of action. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Acide Tranexamique |
|---|---|
| Also known as | Exacyl |
| Sponsor | Centre Hospitalier de Montauban |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acide Tranexamique CI brief — competitive landscape report
- Acide Tranexamique updates RSS · CI watch RSS
- Centre Hospitalier de Montauban portfolio CI
Frequently asked questions about Acide Tranexamique
What is Acide Tranexamique?
Who makes Acide Tranexamique?
Is Acide Tranexamique also known as anything else?
What development phase is Acide Tranexamique in?
Related
- Manufacturer: Centre Hospitalier de Montauban — full pipeline
- Also known as: Exacyl
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing